Boehringer Allies With Quallent For Push On Adalimumab
Follows Confirmation Of Teva-Alvotech Involvement In Deal With Cigna’s Evernorth
Boehringer Ingelheim has revealed that it will supply its 50mg/ml adalimumab biosimilar to Quallent Pharmaceuticals in the US, under a recently-announced initiative that also involves Teva and Alvotech’s 100mg/ml Humira rival.
